Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel
Indication/Tumor Type estrogen-receptor positive breast cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive estrogen-receptor positive breast cancer predicted - sensitive Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel Phase III Actionable In a Phase III trial (CheckMate 7FL), the addition of Opdivo (nivolumab) to neoadjuvant chemotherapy with Taxol (paclitaxel) for 12 weeks followed by Opdivo (nivolumab) plus Cytoxan (cyclophosphamide) and Anthracycline resulted in improved pathologic complete response rate (44.3% vs 20.2%) compared to placebo plus neoadjuvant chemotherapy in patients with high-risk, early stage, ER (ESR1)-positive, CD274 (PD-L1)-positive (CPS>=1%), ERBB2 (HER2)-negative breast cancer (PMID: 39838118; NCT04109066). 39838118
PubMed Id Reference Title Details
(39838118) Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Full reference...